Welcome to our dedicated page for Qualigen Therapeutics news (Ticker: QLGN), a resource for investors and traders seeking the latest updates and insights on Qualigen Therapeutics stock.
Qualigen Therapeutics, now AIxCrypto Holdings, reports developments tied to its completed shift from a clinical-stage biopharmaceutical issuer into an AI and blockchain-focused technology company. News has covered its rebrand, Faraday Future’s controlling investment, private placements, board and executive changes, Nasdaq listing communications, and shareholder approvals tied to capital structure and governance.
Company updates also describe crypto and Web3 initiatives, including the C10 digital-asset treasury, BitGo custody and treasury-management arrangements, Real World Asset tokenization, AI agents, and Embodied AI infrastructure. These announcements frame the company’s operating transition, financing activity, and platform priorities following the Qualigen-era business.
Qualigen Therapeutics (NASDAQ: QLGN) has announced the pricing of a $3.46 million public offering. The offering includes 14,724,058 shares of common stock at $0.13 per share and pre-funded warrants for up to 11,972,754 shares at $0.129 each. The closing is expected around September 6, 2024. Univest Securities, acted as the exclusive placement agent. The company plans to use the net proceeds for various purposes, including:
- Paying off a $2,000,000 Senior Note issued in July 2024
- Advancing clinical trials and preclinical studies
- General working capital
- Possible expansion of relationship with Marizyme, Inc.
- Potential future acquisitions
On May 23, 2024, Qualigen Therapeutics received a delisting notice from Nasdaq due to non-compliance with the minimum bid price requirement and failure to file Form 10-Q for the period ended March 31, 2024. Qualigen's stock has been trading below $1.00 for more than 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). Additionally, the company failed to meet the $2.5 million minimum stockholders’ equity requirement by the extended deadline of May 21, 2024. Qualigen has requested a hearing before a Nasdaq Hearings Panel to stay the suspension of trading and intends to submit a compliance plan. The company's stock will continue to trade under the symbol 'QLGN' during this process.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.